Company Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction.
The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
It also develops ADX-096, a C3d mAb – CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Jodie Morrison |
Contact Details
Address: 830 Winter Street Waltham, Massachusetts 02451 United States | |
| Phone | 781 999 0232 |
| Website | q32bio.com |
Stock Details
| Ticker Symbol | QTTB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661998 |
| CUSIP Number | 746964105 |
| ISIN Number | US7469641051 |
| Employer ID | 47-3468154 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jodie Pope Morrison | Chief Executive Officer and Director |
| Lee H. Kalowski M.B.A. | Chief Financial Officer and President |
| Dr. Jason A. Campagna M.D., Ph.D. | Chief Medical Officer |
| Dr. Shelia M. Violette Ph.D. | Co-founder, Chief Scientific Officer and President of Research |
| Dr. Saul W. Fink Ph.D. | Chief Technology Officer |
| David Appugliese J.D. | Senior Vice President and Head of People |
| Maria Marzilli M.P.H. | Executive Vice President of Corporate Strategy and Program Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 21, 2025 | EFFECT | Notice of Effectiveness |
| Apr 16, 2025 | EFFECT | Notice of Effectiveness |
| Apr 11, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 11, 2025 | S-3 | Registration statement under Securities Act of 1933 |